RegenCen review

A selected dollar price is unconfirmed; the current pages describe discussing treatment and pricing through consultation. The programs have materially different contents. Total Weight & Wellness lasts four months and combines a GLP-1 prescription and guidance with comprehensive labs, check-ins, eight weeks of NAD+ and fifteen weeks of B Fit+. The eight-week reset lists semaglutide, B Fit+ and follow-up. GLP-1 Maintenance focuses on continuing prescribing, monitoring and guidance, while Metabolism Boost is a separate non-GLP-1 offer. Ask for the package name, medication quantity, total obligation and payment dates rather than comparing the names as equivalent monthly plans. Confirm whether dispensing costs sit inside the quote and how later maintenance is charged. Advertised Cherry or PatientFi financing and HSA use do not establish coverage or free credit; any credit agreement needs its own rate and repayment review.

The four-month Total Weight & Wellness package explicitly advertises comprehensive lab work including hormones and ongoing provider check-ins. That is a specific published benefit, so describing all laboratory information as absent would be misleading. It also does not mean the same panel is funded for everyone choosing a different program. The eight-week reset advertises provider-guided follow-up, and maintenance promises progress, symptom and dose monitoring. Neither description establishes the four-month lab allowance, unlimited retesting or a guaranteed number of live visits. Ask which baseline tests are needed for your selected route, whether collection fees are included and who pays if the clinician requests another panel. Establish how check-ins work and whether a change in treatment requires a separately charged appointment. A broad promise of ongoing support should be translated into the actual visit and testing arrangements before you compare quotes.

The current telehealth page specifically identifies Michigan and Florida as its licensed jurisdictions and describes introductory consultations and rechecks there. That supports a two-state virtual-care description, not a national service. Your physical location during the appointment matters; a home address in a covered state does not establish access while traveling elsewhere. The current booking page also lists Michigan and Florida locations. Older articles still mention Bluffton, South Carolina, but those references do not establish a current clinic opening, closure or entitlement to remote treatment. Confirm the exact location and type of appointment you need directly with the practice. RegenCen's broader 20-plus-location description concerns its practice network, not a substitute telehealth eligibility map. If you expect to move or spend substantial time outside the stated service area, ask how follow-up and prescription continuity would be handled before buying a longer program.

RegenCen describes a practice established in 2001, with Gustav Lo as founder and chief medical officer and a clinical mix including physicians, physician assistants and nurse practitioners. Its training and oversight descriptions are attributed practice information, not an independent specialty-board credential or a fresh license check. Ask who will evaluate you and who handles follow-up, especially if choosing the practice for a particular professional's involvement. Separately, its telehealth page names both Belmar in Golden, Colorado, and Olympia in Orlando, Florida. A named partnership is useful supply-chain information but does not assign either facility to every patient or verify the preparation you will receive. Obtain the actual dispenser and formulation for your order. The June 2024 website terms and privacy policy identify CSLC MSO Buyer, LLC and affiliates under CSLC/RegenCen branding; these website disclosures are not a complete patient medication agreement.

The public pages do not establish a complete current cancellation agreement for every GLP-1 program. They do contain relevant restrictions. Telehealth warns that missed appointments incur no-show fees, without giving an amount or notice interval. A compounded-semaglutide shortage article originally published in March 2025 and marked modified March 2026 says medication purchases are final and cannot be returned. Its newer introduction describes current access, but the body retains older stock-up advice and prospective May 2025 language. Treat that final-sale statement as a reason to obtain the policy for your actual order, not as proof that all current services have identical terms. Before payment, ask about cancellation before prescribing or dispatch, clinical denial, unused package services, future refills and financing obligations. Ending clinical treatment, stopping a recurring payment and canceling a credit agreement are separate questions that need clear answers.

The current weight-loss pathway lists medication and injection training after consultation, labs and plan selection. The March 2026 introduction to its shortage article describes self-administered and in-office injection options. Those disclosures show different administration possibilities, but they do not establish home delivery or a complete included kit for every patient. Ask whether your preparation is supplied directly by the selected pharmacy, collected from the practice or administered at an appointment. For home use, get a list of the equipment provided, clear prescription-specific instructions and the contact for questions about administration. Shipping charges, arrival dates and remedies for delayed or temperature-affected medication remain unconfirmed. Ask who handles those issues before the order is processed. An old article's general expiration discussion is not your medication's beyond-use date; follow the actual label and the pharmacist's storage instructions rather than buying quantities based on historical stock-up advice.